Drug Profile
Research programme: protein-misfolding neurodegenerative disorders therapeutics - D-Pharm
Alternative Names: DP-NDD; DP109Latest Information Update: 24 Jul 2023
Price :
$50
*
At a glance
- Originator D-Pharm
- Class Antidementias; Antiparkinsonians; Nootropics
- Mechanism of Action Protein folding modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alzheimer's disease; Amyotrophic lateral sclerosis; Cognition disorders; Huntington's disease; Parkinson's disease
Most Recent Events
- 24 Jul 2023 Discontinued - Preclinical for Alzheimer's disease in Israel (unspecified route)
- 24 Jul 2023 Discontinued - Preclinical for Amyotrophic lateral sclerosis in Israel (unspecified route)
- 24 Jul 2023 Discontinued - Preclinical for Cognition disorders in Israel (unspecified route)